Background: Hormonal treatment for women with breast cancer is frequently proposed in the adjuvant as well as in the palliative setting. Therefore, many women are confronted with early menopause and prolonged oestrogen deprivation and consequently with a variety of quality of life issues, such as menopausal symptoms and fatigue.
Patients And Methods: It was the aim of this study to explore the occurrence and frequency of menopausal symptoms in women with breast cancer, undergoing hormonal cancer treatment and to investigate their relationship with fatigue. A cross-sectional, quantitative approach was used in this multi-centre study. The Checklist for Patients with Endocrine Therapy (C-PET) and the International Breast Cancer Study Group (IBCSG) Linear Analogue Scales for patients with endocrine treatment were used. Descriptive statistics, as well as cluster analyses were performed.
Results: Most frequent menopausal symptoms involved hot flashes/sweats, tiredness, weight gain, vaginal dryness and decreased sexual interest. There were significant differences between the fatigued and the non-fatigued population regarding the intensity of menopausal symptoms, emotional irritability and general coping. Cluster analyses supported a menopausal symptom cluster.
Conclusions: Fatigue accompanies menopausal symptoms and an association can be expected. Methods for routine screening for menopausal symptoms, including fatigue, are suggested as a relevant research issue in women with breast cancer undergoing hormonal treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/annonc/mdl030 | DOI Listing |
Alzheimers Dement
December 2024
Brigham and Women's Hospital and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Virtually all adults with Down Syndrome(DS) show Alzheimer's disease(AD)-related pathologic change by the age of 40 years. While sex differences in Aβ-dependent tauopathy are apparent during early sporadic AD, sex differences in the DS population remain under-investigated. Moreover, menopause onset occurs earlier in the DS population (45 years), and it remains unknown whether menopause status and hormone therapy(HT) exposure influences Aβ-dependent tauopathy in women with DS.
View Article and Find Full Text PDFBackground: Alzheimer's affects women 2:1 compared to men, suggesting sex-specific factors driving risk. Menopause, a female-specific phenomenon, induces a multi-system response across endocrine, metabolic, and immune-inflammatory systems. Despite known effects on these systems, the impact on the brain and AD risk remains incompletely understood, limiting preventative options.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Brighton & Sussex Medical School, Brighton, United Kingdom.
Background: Reported effects of Hormone Replacement Therapy (HRT) on late-life neurodegenerative disease are inconsistent. Variability in the timing and formulation of HRT, plus whether an individual carries an Apolipoprotein (APOE) e4 genetic risk variant for Alzheimer's Disease (AD), likely contribute to conflicting results. Additionally, whilst many studies have focused exclusively on the effects of exogenous oestrogen, the inclusion of testosterone in HRT appears protective against AD pathology, specifically in APOE e4 carriers.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Hormone therapy (HT) is often used to manage symptoms related to menopause, but its longer-term effects on depressive symptoms in older women remains unclear. Previous literature reports inconclusive results on whether HT use is protective against or associated with increased depressive symptoms over time in older women. The objective of this study was to examine the associations of self-reported HT use with baseline and longitudinal later life depressive symptoms.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Brigham and Women's Hospital and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Virtually all adults with Down Syndrome(DS) show Alzheimer's disease(AD)-related pathologic change by the age of 40 years. While sex differences in Aß-dependent tauopathy are apparent during early sporadic AD, sex differences in the DS population remain under-investigated. Moreover, menopause onset occurs earlier in the DS population(45 years), and it remains unknown whether menopause status and hormone therapy(HT) exposure influences Aß-dependent tauopathy in women with DS.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!